LBF20303TX01: Difference between revisions

No edit summary
 
(14 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Lipid/Header}}
{{Hierarchy|{{PAGENAME}}}}
{{Hierarchy|{{PAGENAME}}}}


Line 4: Line 6:
|LipidBank=XPR2002
|LipidBank=XPR2002
|LipidMaps=LMFA03030005
|LipidMaps=LMFA03030005
|SysName=7- [ 3- (3 (S) -Hydroxy-1 (E) ,5 (Z) -octadienyl) -1 (S) ,5 (S) ,4,6-dioxabicyclo [ 3.1.1 ] hept-2-yl ] -5 (Z) -heptenoic acid
|SysName=7- [3- (3S-Hydroxy- (trans-1,cis-5) -octadienyl) -(1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -cis-5-heptenoic acid
|Common Name=&&THROMBOXANE A3&&7- [ 3- (3 (S) -Hydroxy-1 (E) ,5 (Z) -octadienyl) -1 (S) ,5 (S) ,4,6-dioxabicyclo [ 3.1.1 ] hept-2-yl ] -5 (Z) -heptenoic acid&&
|Common Name=&&Thromboxane A_3&&7- [3- (3S -Hydroxy- (1E,5Z) -octadienyl) -(1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -5(Z) -heptenoic acid&&
|Source=
|Chemical Synthesis=
|Metabolism=Prostaglandin H3 is produced from 5,8,11,14,17-eicosapentaenoic acid, which is one-eighth as efficient a substrate as arachidonic acid, by the catalysis of fatty acid cyclooxygenase, and then transformed to unstable thromboxane A3 [[Reference:Needleman_P:Raz_A:Minkes_MS:Ferrendelli_JA:Sprecher_H:,Proc. Natl. Acad. Sci. U. S. A.,1979,76,944|{{RelationTable/GetFirstAuthor|Reference:Needleman_P:Raz_A:Minkes_MS:Ferrendelli_JA:Sprecher_H:,Proc. Natl. Acad. Sci. U. S. A.,1979,76,944}}]], which is converted non-enzymatically to stable thromboxane B3.
|Symbol=TXA3
|Biological Activity=Thromboxane A3 did not cause platelet aggregation unlike thromboxane A2, and inhibited platelet aggregation by other agonists [[Reference:Needleman_P:Raz_A:Minkes_MS:Ferrendelli_JA:Sprecher_H:,Proc. Natl. Acad. Sci. U. S. A.,1979,76,944|{{RelationTable/GetFirstAuthor|Reference:Needleman_P:Raz_A:Minkes_MS:Ferrendelli_JA:Sprecher_H:,Proc. Natl. Acad. Sci. U. S. A.,1979,76,944}}]].
}}
}}
{{Lipid/Footer}}

Latest revision as of 07:06, 21 October 2010

LipidBank Top
(トップ)
Fatty acid
(脂肪酸)
Glycerolipid
(グリセロ脂質)
Sphingolipid
(スフィンゴ脂質)
Journals
(雑誌一覧)
How to edit
(ページの書き方)


Upper classes: LB LBF



Thromboxane A3
LBF20303TX01.png
Structural Information
7- [3- (3S-Hydroxy- (trans-1,cis-5) -octadienyl) -(1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -cis-5-heptenoic acid
  • Thromboxane A3
  • 7- [3- (3S -Hydroxy- (1E,5Z) -octadienyl) -(1S,5S,4,6) -dioxabicyclo [ 3.1.1 ] hept-2-yl] -5(Z) -heptenoic acid
TXA3
Formula C21H32O4
Exact Mass 348.23005951199997
Average Mass 348.47637999999995
SMILES C([C@H]([C@H](C=C[C@H](O)CC=CCC)2)[C@@H](C1)O[C@H](C2)1)C=CCCCC(O)=O
Physicochemical Information
Prostaglandin H3 is produced from 5,8,11,14,17-eicosapentaenoic acid, which is one-eighth as efficient a substrate as arachidonic acid, by the catalysis of fatty acid cyclooxygenase, and then transformed to unstable thromboxane A3 Needleman_P et al., which is converted non-enzymatically to stable thromboxane B3.
Thromboxane A3 did not cause platelet aggregation unlike thromboxane A2, and inhibited platelet aggregation by other agonists Needleman_P et al..
Spectral Information
Mass Spectra
UV Spectra
IR Spectra
NMR Spectra
Other Spectra
Chromatograms
Reported Metabolites, References
Biospecies ID Compound Name Reference Comment
n.a. LBF20303TX01 See above. Needleman_P et al. 1979